# SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients

Source: https://onco.cc/trials/nct03448549/  
OnCo record `nct03448549` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Oxaliplatin, Tegafur, gimeracil and oteracil and Capecitabine in Colorectal cancer, run by Peking University Cancer Hospital & Institute, with a status the registry has not verified recently.

## Summary

SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients is a phase 3 interventional study registered as NCT03448549 by Peking University Cancer Hospital & Institute, with 1191 participants planned, started 2018-01-01 and due to reach its primary completion in 2021-01-01. Interventions recorded: Oxaliplatin, Tegafur，gimeracil and oteracil potassium, Xeloda. Conditions recorded: Colorectal Cancer Stage III, Adjuvant Chemotherapy.

Linked to the drug Tegafur, gimeracil and oteracil because the registry names it among its interventions and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03448549
- Phase: 3
- Setting: A Prospective Randomized Controlled Trial to Compare Oxaliplatin Combined With S-1 (SOX) Versus Oxaliplatin With Capecitabine (XELOX) as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients
- Sponsor: Peking University Cancer Hospital & Institute
- Enrolled: 1191

## Sources

- ClinicalTrials.gov NCT03448549: https://clinicaltrials.gov/study/NCT03448549

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Tegafur, gimeracil and oteracil (S-1)](https://onco.cc/drugs/tegafur-gimeracil-oteracil/)

---
JSON: https://onco.cc/api/v1/entities/nct03448549.json